Biomedicines (Jul 2023)

A2AR Expression and Immunosuppressive Environment Independent of <i>KRAS</i> and <i>GNAS</i> Mutations in Pseudomyxoma Peritonei

  • Shigeki Kusamura,
  • Adele Busico,
  • Elena Conca,
  • Iolanda Capone,
  • Luca Agnelli,
  • Daniele Lorenzini,
  • Silvia Brich,
  • Marta Angelini,
  • Chiara Costanza Volpi,
  • Desirè Viola Trupia,
  • Vincenzo Lagano,
  • Tommaso Torelli,
  • Annunziata Gloghini,
  • Dario Baratti,
  • Marcello Guaglio,
  • Massimo Milione,
  • Marcello Deraco,
  • Federica Perrone

DOI
https://doi.org/10.3390/biomedicines11072049
Journal volume & issue
Vol. 11, no. 7
p. 2049

Abstract

Read online

In pseudomyxoma peritonei (PMP), KRAS and GNAS mutations are frequent. We hypothesized that these mutations may contribute to the suppression of antitumor immunity: KRAS may induce GMCSF expression, while GNAS may enhance the expression of cyclic adenosine monophosphate and A2AR signaling. This study aimed to explore possible mechanisms facilitated by KRAS and GNAS mutations for escaping immune surveillance. Additionally, we looked for new potential therapeutic and prognostic targets in this rare disease which is poorly characterized at the molecular level. GM-CSF, A2AR, CD73, CD39, and PD-L1 expression was investigated by immunohistochemistry in 40 PMPs characterized for GNAS and KRAS mutational status. Immune cell populations were studied by immunohistochemistry and nanostring nCounter®. Following the criteria of a prognostic nomogram reported for PMP, we stratified the patients into two different risk groups, with 28 “low-risk” and 12 “high-risk” patients. We observed the expression of GM-CSF (74%); CD39 (37%); CD73 (53%); A2AR (74%); and PD-L1 (16%) which was unrelated to GNAS or KRAS status. The tumor microenvironment showed the presence of CD4+ T cells (86%); CD8+ T cells (27%); CD20+ B (67%); CD15+ cells (86%); and CD163+ M2 macrophages (67%), while CD56+ NK cells were absent. CD163 expression (27%) in PMP tumor cells was associated with poor prognosis. GNAS mutation and A2AR expression were not associated with a specific immune transcriptional signature. However, the expression assay revealed 21 genes associated with prognosis. The “high-risk” patients exhibited worse progression-free survival (HR = 2.3, CI 95%: 1.1–5.1, p = 0.034) and significant downregulation of MET, IL8, PPARG, DTX4, HMGA1, ZIC2, WNT5B, and CCRL2. In conclusion, we documented the presence of immunosuppressive factors such as GM-CSF, A2AR, and PD-L1 in PMP. These factors were not associated with GNAS and KRAS status and could be explored as therapeutic molecular targets. Additionally, a set of potential prognostic biomarkers, including CD163 expression in tumor cells, deserve further investigation.

Keywords